

Kinser, Robin D.

From: Kirk.Newland@mdsps.com
Sent: Wednesday, September 03, 2003 3:11 PM
To: daryl.grafelman@mdsps.com; toby.julian@mdsps.com; serita.karmazin@mdsps.com; patricia.spilker@mdsps.com; Robin.D.Kinser@pmusa.com; Shixia.feng@pmusa.com; hans-juergen.roethig@pmusa.com; jan.oey@pmusa.com; kimberly.prchal@mdsps.com; robert.earl@mdsps.com; gaylin.nickell@mdsps.com; peggy.ruhn@mdsps.com; chenier.dodard@mdsps.com; rudolf.guilbaud@mdsps.com; josee.michon@mdsps.com; jacques.prevast@mdsps.com; Nathalie.rouselle@mdsps.com; Ginette.Gauthier-Dubois@mdsps.com; jaimie.stark@mdsps.com; francis.beaudry@mdsps.com; alan.dzerk@mdsps.com; roger.coe@mdsps.com; jean.lee@mdsps.com; joanne.hilgert@mdsps.com; jessica.kopejtka@mdsps.com
Subject: Research and Development Update for the week of 03-Sep-2003



PM update
33-03.doc (125 K)

Attached is the research and development update for the week of 03-Sep-2003.

Kirk Newland
Validation Team Leader
MDS Pharma Services, Inc.
621 Rose Street
Lincoln, NE 68502 USA
Tel: (402) 437-4719
Fax: (402) 476-7598
E-mail: kirk.newland@mdsps.com

(See attached file: PM update 09-03-03.doc)